Introduction {#Sec1}
============

Fever and pain occur frequently in infants and children \[[@CR1]\]. Management of fever tends to be characterized by over-treatment, because of the parents anxiety and fever phobia \[[@CR2]--[@CR6]\], whereas management of pain is characterized by under-treatment, particularly in very young children with acute painful injuries \[[@CR7], [@CR8]\]. Paracetamol is a common analgesic and antipyretic drug for management of fever and mild-to-moderate pain in pediatric patients. It is the first-line choice for the treatment of both fever and pain according to national and international guidelines and recommendations and it is also included in the List of Essential Medicines for Children of the World Health Organization (WHO) \[[@CR9]--[@CR20]\].

Appropriate dosages should be used to ensure optimal efficacy and safety of paracetamol \[[@CR18]\]. Given the wide range of body weight across children of different ages, guidelines for treatment of pain highlight the importance of administering the correct dose according to body weight, hence the use of milligram per kilogram (mg/kg) dosing \[[@CR10], [@CR12], [@CR14], [@CR15], [@CR18]\]. Pediatric patients, especially if they have fever or pain, are acutely unwell may be frightened and less co-operative than usual \[[@CR21]\]. Flexible formulations should guarantee the ease of administration and aid dosing accuracy. Specific oral formulations of paracetamol, as syrup and drops, should be recommended because easy to administer and because they allow selection of the right mg/kg dose. Paracetamol recommended doses vary from 10 to 15 mg/kg every 4--6 h (up to 60 mg/kg/day) \[[@CR9], [@CR14], [@CR18], [@CR22]\]. A common issue is the variability of dosages used to treat fever and pain in clinical practice, where paracetamol doses range from 5 to 20 mg/kg \[[@CR9], [@CR23]--[@CR25]\]. Studies have shown that dose variability can depend on to the specialty of the prescribing physician, with pediatricians prescribing more suitable doses than family physicians or otolaryngologists \[[@CR23]\].

Clinical trials have investigated different doses, with older trials focusing on doses \<10 mg/kg, now known to be subtherapeutic \[[@CR26]--[@CR33]\]. More recent studies have investigated higher oral paracetamol doses 10--30 mg/kg \[[@CR34]--[@CR40]\] and the available evidence now suggests that 15 mg/kg could be the optimal dose.

The objective of this article was to review the literature and identify the analgesic and antipyretic doses of paracetamol that guarantee efficacy and safety in children. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Methods {#Sec2}
=======

A systematic literature search was performed in Medline using the search terms \["pain" OR "fever" OR "migraine"\] AND "child" AND "acetaminophen" (paracetamol) AND \["dose" or "dosing" or "dosage" or "dose-related"\], both as subject headings and keywords. Papers with acetaminophen indexed as adverse effect, contraindication, metabolism, pharmacokinetics, pharmacology, therapeutic use, and toxicity were selected. No restrictions were applied to the other search terms. The search was limited to children with no date or other limits applied. The search results were de-duplicated and papers relevant to this review were selected manually. Other supporting references were sourced by specific literature searches as required, or were obtained from bibliographies of review articles or from the authors' personal libraries.

Results of Literature Search {#Sec3}
============================

A total of 114 papers were found. Of these, 53 papers explicitly mentioning mg/kg dosing of paracetamol were manually selected for potential inclusion in this review. Of these, 14 were review articles, 4 were pharmacokinetic (PK)/pharmacodynamics (PD) studies, 2 were meta-analyses of clinical trials, and 23 were clinical studies of paracetamol in children either as the only arm or as one of the study arms (21 specifically studied paracetamol 15 mg/kg and 2 studied paracetamol 12 mg/kg). Papers reporting trials of 10 mg/kg or lower doses were included for comparative purposes, but are not discussed in depth.

Pharmacology {#Sec4}
============

Pharmacokinetics {#Sec5}
----------------

Paracetamol is a highly lipid-soluble compound that is readily absorbed through the gut \[time to peak drug concentration (*T*~max~) 0.5--0.75 h after oral administration\], with a bioavailability of nearly 90% \[[@CR41]--[@CR43]\]. It has a pKa of 9.5 and is therefore highly polarized in the stomach with very low gastric absorption \[[@CR44]\]. Once in the basic environment of the duodenum, paracetamol rapidly crosses the mucosa and enters the bloodstream. Paracetamol shows a negligible binding to plasma proteins (10--25%), a key feature that differentiates it from other analgesics/antipyretics such as ibuprofen \[[@CR24], [@CR42]\]. Paracetamol is metabolized principally in the liver. In adults, glucuronide and sulfate conjugates account for 50--60% and 25--30%, respectively, and \<10% remain unmodified. In children, though the metabolic pathways are the same, their relative contributions change with age, since the sulfation pathways are mature at birth while the glucuronidation pathways matures in about 2 years \[[@CR24], [@CR41]\]. Almost 90% of paracetamol metabolites are excreted into the urine within 24 h \[[@CR24]\]. Paracetamol half-life (*t*~½~) is short, ranging from 2 to 2.5 h \[[@CR41]\].

A key issue when dealing with paracetamol pharmacology is the "effect compartment" concept that explains the time delay between therapeutic levels of paracetamol in the plasma and analgesic or antipyretic effect \[[@CR24], [@CR45]\]. The therapeutic effect of paracetamol is not linearly related to plasma concentration. Both antipyresis and analgesia are related to concentrations reached in the brain, with paracetamol needing to exit the bloodstream and reach the neural tissue before exerting its effects \[[@CR24]\]. This effect compartment model has key clinical implications, both for dosing levels and dosing schedules.

The administered dosage influences the speed of onset of action and the achieved plasma concentrations, so that appropriate dosing to achieve suitable effect compartment concentrations is crucial for maximum efficacy \[[@CR45]\].

Pharmacodynamics {#Sec6}
----------------

The mechanism of action of paracetamol is still debated. It was first hypothesized that the drug exerts its effect via inhibition of prostaglandin synthesis by cyclooxygenase (COX); it is now known that paracetamol has several PD targets within the brain. Paracetamol inhibits COX and reduces prostaglandin synthesis, with an interaction site different from that of non-steroidal anti-inflammatories (NSAIDs) \[[@CR46], [@CR47]\]. NSAIDs inhibit prostaglandin synthesis by competing with arachidonic acid for the COX binding site, whereas paracetamol reduces prostanoid formation by acting at the peroxidase site \[[@CR46], [@CR47]\]. More precisely, paracetamol is thought to act as a reduction factor, donating electrons to the radical Fe^4+^ within the COX peroxidase site, thereby preventing the generation of tyrosine radials and, in turn, preventing arachidonic acid oxygenation \[[@CR47]\]. Due to the large amounts of hydroperoxide present in inflammatory environments \[[@CR48]\], the activity of paracetamol is diminished because cellular hydroperoxide oxidizes the radical Fe within the peroxidase site, preventing the effect that paracetamol has on arachidonic acid oxygenation \[[@CR47]\]. Generally, hydroperoxide is present in large amounts in inflammatory environments, reducing paracetamol activity.

These findings explain why paracetamol cannot counteract inflammation and platelet aggregation, as well as its exclusive central nervous system (CNS) activity \[[@CR24]\]. Several lines of evidence demonstrate that the ability of paracetamol to reduce fever is due to inhibition of hypothalamic prostaglandin formation \[[@CR24]\]. Fever occurs when warm-sensitive neurons, normally responsible for triggering heat loss, are inhibited by prostaglandins, mainly prostaglandin E2 (PGE2) \[[@CR20]\]. By inhibiting COX in neural and brain endothelial cells, paracetamol counteracts PGE2 formation, thereby relieving suppression of warm-sensitive neurons that are then free to reset thermoregulation toward lower body temperature \[[@CR49]\]. Therefore, mechanism of antipyresis by paracetamol occurs through the canonical inhibition of COX within the CNS, akin to that exerted by classic NSAIDs.

The mechanisms of the analgesic effect of paracetamol differ from that of NSAIDs. Several lines of evidence indicate that in addition to COX inhibition, the descending, serotonergic pain control system is also associated with paracetamol analgesia \[[@CR24], [@CR47]\]. This occurs via indirect activation of serotonin receptors, including the 5 hydroxytryptamine~3~ (5HT~3~) subtype, on opioidergic interneurons that, in turn, reduce excitability of dorsal horn neurons projecting to the thalamus \[[@CR21]\]. Accordingly, the 5HT~3~ receptor antagonists tropisetron or granisetron completely prevent analgesia prompted by 1 g oral paracetamol \[[@CR50], [@CR51]\]. An additional mechanism through which paracetamol prompts analgesia might be its transformation into *N*-arachidonyl-aminophenol (also called AM404) by fatty acid hydrolase, an enzyme highly expressed within the brain. AM404 activates TRPV1 on terminal of nociceptors, but also inhibits COX1-2, and favors cannabinoid receptor-1 (CB1)-dependent analgesia by counteracting cellular uptake of the endogenous CB1 receptor agonist anandamide \[[@CR24], [@CR47]\].

Antipyresis by Paracetamol: Pharmacology-Based Practical Implications {#Sec7}
=====================================================================

Due to indisputable ethical reasons, repetitive cerebrospinal fluid (CSF) sampling cannot be obtained in children for research. As a consequence, maximal antipyretic effects (*E*~max~) or the plasma/CSF concentration producing half of *E*~max~ (EC~50~) are merely estimated from empirical data deriving from specific assessments. PK studies of paracetamol report an *E*~max~ of 3 °C and a plasma EC~50~ of 9.7 mg/L obtained with classic doses of 10--15 mg/kg \[[@CR52], [@CR53]\]. Although evidence suggests that paracetamol 10--12.5 mg/kg is effective at antipyresis in children, as mentioned above there is a delay between the achievement of appropriate paracetamol concentrations and onset of action \[[@CR24]\]. This time delay is a key aspect of practical treatment of fever in children, so augmenting the dose or selecting the highest dose is most likely to provide the onset and duration of action necessary for clinical improvement. Gibb and Anderson \[[@CR45]\] suggested that increasing the paracetamol dose would speed up onset of antipyresis. A recent analysis of data from 3155 feverish children receiving paracetamol in 53 studies partly confirms Gibb and Anderson estimation \[[@CR25]\].

Temple et al. \[[@CR25]\] also showed that 15 mg/kg produced a larger relative temperature reduction and a longer duration of substantial temperature reduction compared with 10 mg/kg. After 30 min, 15 mg/kg paracetamol decreased body temperature by 0.71 °C, while 10 mg/kg paracetamol reduced body temperature by 0.36 °C (i.e., only 0.4 °C higher than that achieved with the lower dose). However, duration of antipyresis was substantially longer with the dose of 15 mg/kg. 15 mg/kg oral paracetamol was associated with a mean temperature reduction of about 1 °C greater than that observed with the 10 mg/kg dose after 8 h (−1.35 vs. −0.65 °C change in temperature with 15 and 10 mg/kg at 8 h, respectively) \[[@CR25]\]. A review summarizing available PK/PD (fever reduction) data of oral paracetamol in children aged 6 months to 12 years concluded that the antipyretic effect of paracetamol is dose dependent \[[@CR22]\]. In the dose range of 10--15 mg/kg, paracetamol was more effective than placebo in this analysis. Variables such as the initial temperature and the age of the patient can influence the antipyretic response of paracetamol \[[@CR42]\]. Taken together, data indicate that 15 mg/kg, allowing an earlier onset and a longer duration of effect is an optimal, oral paracetamol dose for an antipyretic effect.

Analgesia by Paracetamol: Pharmacology-Based Practical Implications {#Sec8}
===================================================================

The molecular mechanisms responsible for fever reduction and analgesia by paracetamol differ substantially. The pleiotypic mechanisms of paracetamol-induced analgesia have important consequences in determining the correct use of this drug for the efficient treatment of pain. A key aspect of paracetamol analgesia is that it occurs at CNS drug concentrations higher than those required for antipyresis \[[@CR24]\]. Specifically, it has been reported that plasma EC~50~ of antipyresis (4.63 mg/L) is almost half of that of analgesia (9.98 mg/L) \[[@CR45]\].

Although the pharmacological basis of the higher plasma EC~50~ required to treat pain still needs to be unequivocally determined, it is conceivable that it is mainly related to the various mechanisms of paracetamol analgesia. Indeed, it is plausible that the drug must reach CNS concentrations higher than those able to inhibit COX to fully activate the pain-suppressing effect on opioid receptor and descending serotonergic pathway. These different PD features translate into different therapeutic approaches in the clinical setting, altering the practical use of the drug when treating fever or pain in children to obtain maximal therapeutic benefit.

The time delay caused by the effect compartment must also be taken into account when choosing an appropriate dose of paracetamol, since there is a threshold concentration required in the CNS before analgesic activity is produced, and under-dosing results in a delay in pain reduction. The minimum target effect compartment concentration is 11.8 mg/L for pain relief in children. At least 15 mg/kg is required orally to achieve analgesic paracetamol levels \[[@CR54]\]. The possible time delay should also drive the choice of time interval between repeated doses, so that appropriate steady-state plasma levels are reached in a timely manner.

Unfortunately, the time--concentration relationship has not been determined after multiple paracetamol dosing. However, it is possible to extrapolate such a relationship by analyzing data from the literature. Specifically, evidence that a dose of 15 mg/kg in adults leads to a peak drug concentration (*C*~max~) of 11.8 mg/L \[[@CR55], [@CR56]\], together with the notion that in the plasma concentrations increase linearly with dose, allows an estimation of a *C*~max~ of 12.6 mg/L following a dose of 15 mg/kg. This information along with that provided by the study by Hopkins et al. \[[@CR57]\] which showed plasma *T*~max~ and *t*~½~, respectively, of 114 and 138 min in children receiving 15 mg/kg of oral paracetamol means an approximate time/concentration relationship describing plasma values in children can be constructed (Fig. [1](#Fig1){ref-type="fig"}). To determine this relationship following multiple oral doses of 15 mg/kg, the data from the study by Nahata et al. \[[@CR58]\], which reported a 13.35% plasma accumulation at the steady state in children receiving this dose in a repetitive dosing paradigm, can be employed. Combining these PK parameters produces a time/plasma concentration curve after repetitive (every 6 h) 15 mg/kg oral dosing (Fig. [2](#Fig2){ref-type="fig"}). This estimation indicates that steady state of plasma concentrations of 14.28 mg/L is reached within 20 h after initiating repetitive dosing. Remarkably, steady-state concentrations of 14.28 mg/L are above the pain threshold of 11 mg/L identified by the study by Brett and colleagues \[[@CR54]\]. These extrapolations suggest that oral dosing of paracetamol at 15 mg/kg every 6 h permits rapid achievement of steady-state concentrations and *C*~max~ well above those required to prompt analgesia. Still, to expedite onset of pain resolution, adoption of a loading dose will obviously shift the time--concentration curve depicted in Fig. [1](#Fig1){ref-type="fig"} upward, thereby allowing faster attainment of steady state. Remarkably, these data, based both on empirical findings and estimations, nicely fit with guidelines proposed by different institutions: that regimens of 15 mg/kg oral paracetamol every 6 h provide efficient pain control in children \[[@CR14]\].Fig. 1Time--concentration relationship after oral paracetamol 15 mg/kg. The minimum target effect compartment concentration is 11.8 mg/L for pain relief in children. Oral paracetamol 15 mg/kg is required for the optimal analgesic effect. *C* ~*max*~ peak drug concentration, *t* ~*1/2*~ half-lifeFig. 2Time--concentration relationship after multiple paracetamol 15 mg/kg oral doses. Oral paracetamol 15 mg/kg every 6 h (a "by the clock" and not "as needed" treatment regimen) permits rapid achievement of steady-state concentrations well above the analgesic threshold

Clinical Management of Fever with Paracetamol {#Sec9}
=============================================

The pharmacological treatment of fever in children and infants should be carried to reduce the discomfort of the child, not to fight fever per se. Frequently, fever in children causes anxiety in the parents that if not properly managed can lead to mistakes, even in the choice of medication and the appropriate dose.

In general, paracetamol is the only antipyretic approved for use in children from birth and it is indicated as the drug of choice in pediatric guidelines for the management of fever in children \[[@CR13], [@CR15]\]. Unlike ibuprofen, which is approved for use in children over 3 years of age, paracetamol is indicated in patients with chickenpox and in those with dehydration and pneumonia \[[@CR13], [@CR14]\].

Clinical Trial Data {#Sec10}
-------------------

Clinical data for 15 mg/kg paracetamol in children with fever are summarized in Table [1](#Tab1){ref-type="table"}. These studies investigated paracetamol 12--15 mg/kg vs. ibuprofen \[[@CR34], [@CR35], [@CR40], [@CR59], [@CR60]\], ketoprofen \[[@CR59]\], dipyrone \[[@CR40]\], and placebo \[[@CR38], [@CR61]\]. Compared with ibuprofen and ketoprofen, paracetamol 15 mg/kg had a comparable efficacy \[[@CR34], [@CR35], [@CR40], [@CR59], [@CR60]\]. Dipyrone was more effective than paracetamol at temperature normalization and temperature reduction \[[@CR40]\]. Compared with placebo, paracetamol showed a better efficacy profile \[[@CR38], [@CR61]\]. Ibuprofen, ketoprofen and dipyrone used for short term had similar safety profile to paracetamol \[[@CR34], [@CR35], [@CR40], [@CR59], [@CR60]\] that in turn shows a similar or better tolerability profile to placebo (Table [1](#Tab1){ref-type="table"}) \[[@CR38], [@CR61]\].Table 1Summary of clinical trials of paracetamol for treatment of fever in childrenStudy (design; setting)Patients (*N*; age range)Treatments (*n*)RegimenEfficacy endpointEfficacy results (PARA vs. comparator)Adverse events (PARA vs. comparator)Versus NSAIDs Autret-Leca et al. \[[@CR34]\]. (R, DB \[1st dose\]/OL \[3 days\], MC, PG; GP)Fever (304; 0.25--12 years)PARA 15 mg/kg (150)\
IBU 10 mg/kg (151)Repeat dose for 3 daysAUC~0-6 h~Mean AUC~0--6 h~\
−7.66 vs. −7.77 °C/min (*P* = 0.82)Any AE\
10.6% vs. 11.2%\
Infections\
4.6% vs. 3.3%\
GI disorders\
2.6% vs. 2.6%\
Respiratory disorders\
2.6% vs. 2.6% Carabano et al. \[[@CR35]\]. (PG; NR)Fever, ≥38 °C (166; NR)PARA 15 mg/kg (80)\
IBU 7 mg/kg (86)Single doseChange in temperature after drug administrationAt 1 h\
37.80 vs. 37.66 °C (*P* = 0.22)\
At 2 h\
37.29 vs. 37.09 °C (*P* = 0.14)\
At 3 h\
37.28 vs. 37.12 °C (*P* = 0.64)\
At 4 h\
37.46 vs. 37.40 °C (*P* = 0.72)NR Celebi et al. \[[@CR59]\]. (R, PG; ED)Fever (301; 1--14 years)PARA 15 mg/kg (112)\
IBU 10 mg/kg (84)\
KETO 0.5 mg/kg (105)Repeat dose for 48 hChange in temperature after drug administrationAt 30 min\
38.4 vs. 38.5 vs. 38.4 °C\
At 60 min\
38.0 vs. 38.1 vs. 37.9 °C\
At 120 min\
37.7 vs. 37.7 vs. 37.6 °C\
At 4--6 h\
37.5 vs. 37.4 vs. 37.3 °CEarly (\< 6 h) vomiting\
3.8% vs. 9.6% vs. 13.5%\
Late (6--48 h) vomiting\
1.3% vs. 5.8% vs. 2.7% PITCH \[[@CR60]\]. (R, SB, MC, PG; OP)Fever, ≥37.8 °C and ≤41.0 °C (156; 0.5--6 years)PARA 15 mg/kg^a^ (52)\
IBU 10 mg/kg^b^ (52)\
PARA + IBU (52)Repeat dose for 48 hTime without fever in the first 4 hTime without fever in the first 4 h\
219 vs. 211 vs. 202 min\
Time without fever in the first 24 h\
1078 vs. 1029 vs. 1051 minDiarrhea\
19.2% vs. 17.3% vs. 23.1%\
Vomiting\
11.5% vs. 5.8% vs. 3.8%\
Rash\
3.8% vs. 3.8% vs. 1.9% Wong et al. \[[@CR40]\]. (R, DB, MC, PG; NR)Fever, ≥ 37.8 °C and ≤ 40.5 °C (628; 0.5--6 years)PARA 12 mg/kg^c^ (210)\
DIPYR 15 mg/kg (209)\
IBU 5/10 mg/kg^d^ (209)Single dosePatients with a temperature reduction of ≥1.5 °CTemperature reduction of ≥1.5 °C\
77% vs. 86% vs. 83%\
Time to temperature reduction of ≥1.5 °C\
109 vs. 103 vs. 120 min\
Normal (≤37.5 °C) temperature\
68% vs. 82% vs. 78%\
(both *P* = 0.004 vs. PARA)Drug-related AEs\
15% vs. 17% vs. 27%\
Vomiting\
3.8% vs. 4.3% vs. 2.9%\
Diarrhea\
2.4% vs. 1.4% vs. 1.4%Versus PL Gupta et al. \[[@CR38]\]. (R, DB, PC; tertiary care)Fever, ≥ 37.6 °C and ≤ 40.5 °C (210; 0.5--6 years)PARA 15 mg/kg (103)\
PL (107)Single doseFever clearance time \[time to normal (≤37.5 °C) temperature\]Median fever clearance time\
32 vs. 36 h\
(*P* = 0.23)AE in first 6 h\
8.7% vs. 0% Kramer et al. \[[@CR61]\]. (R, DB, PC; home)Fever, ≥ 38 °C and \< 41 °C (225; 0.5--6 years)PARA 10--15 mg/kg (123)\
PL (102)Multiple dose q4 hDuration of feverMean duration of fever\
34.7 vs. 36.1 hNRParenteral PARA (i.e., PROP) Reymond et al. \[[@CR84]\]. (Two studies; R, OL, PG; hospital)Fever (10/24; NR)Study 1\
PROP 30 mg/kg (5)\
ASA 15 mg/kg (5)\
Study 2\
PROP 30 mg/kg (11)\
PROP 15 mg/kg (13)Single doseChange in temperatureStudy 1: change in temperature\
−1.99 vs. −2.31 °C\
Study 2: change in temperature\
−1.79 vs. −2.11 °CBurning sensation during PROP infusion in 45% of patientsDrug-dosage comparison Treluyer et al. \[[@CR36]\]. (R, DB, PG; NR)Fever, 39--40.5 °C (121; 0.33--9 years)PARA 30 mg/kg LD (62)\
PARA 15 mg/kg MD (59)Single doseRectal temperatureTime to rectal temperature \<38.5 °C\
110.7 vs. 139.4 min\
(*P* = 0.05)Any AE\
9.7 vs. 8.5%*AUC* ~*0*--*6h*~ area under the temperature reduction curve-absolute difference in tympanic temperature from baseline at 6 h, *ASA* aspirin, *DB* double blind, *DIPYR* dipyrone, *ED* emergency department, *GI* gastrointestinal, *GP* general practice, *IBU* ibuprofen, *KETO* ketoprofen, *LD* loading dose, *MD* maintenance dose, *NR* not reported, *NSAIDs* non-steroidal anti-inflammatory drugs, *OL* open label, *OP* outpatient, *PARA* paracetamol, *PL* placebo, *PC* placebo-controlled, *PG* parallel group, *PROP* propacetamol, *q4* *h* Every 4 h, *R* randomized, *SB* single blind^a^Every 4--6 h^b^Every 6--8 h^c^Dosed according to age; average was 12 mg/kg^d^5 mg/kg for T0 \< 39.2 °C; 10 mg/kg for T0 ≥ 39.2 °C

Other studies have shown similar results. A recent systematic review of clinical data showed that the 10--15 mg/kg oral dose first recommended in 1983 is still appropriate for the treatment of fever in children \[[@CR25]\]. However, as mentioned above, the same review also showed data in which 15 mg/kg paracetamol was better at reducing temperature for longer time than 10 mg/kg paracetamol, the mean maximum temperature decrease from baseline was 1.17 °C in the 10 mg/kg studies and 1.60 °C in the 15 mg/kg studies, and the temperature decrease from baseline at 480 min was 0.65 °C in the 10 mg/kg studies and 1.35 °C in the 15 mg/kg studies \[[@CR25]\]. These results are supported by additional clinical trials of 10 mg/kg, paracetamol which generally was consistently less effective than ibuprofen \[[@CR27]--[@CR29], [@CR62]\]. The importance of choosing the right dose of paracetamol to treat fever should be strongly stressed, since a low dose could compromise effectiveness, and physicians should carefully choose the dose of paracetamol guaranteeing antipyretic efficacy and safety in children. The clinical trial data presented suggest that paracetamol 15 mg/kg is the most appropriate choice for rapid and effective fever reduction.

Clinical Management of Pain with Paracetamol {#Sec11}
============================================

In children with pain and headache, the recommended dose of paracetamol is 10--15 mg/kg administered 3--4 times a day to a maximum dose of 60 mg/kg/day \[[@CR18], [@CR19]\]. The most appropriate medication for the treatment of pain should be chosen based on the underlying cause of the pain. Options include NSAIDs and paracetamol. Paracetamol is not recommended for anti-inflammatory use \[[@CR63]\]; however, it is the most appropriate drug in children with pain of a non-inflammatory etiology \[[@CR15], [@CR18]\]. A systematic review investigated paracetamol as an opioid-sparing treatment in children with perioperative pain \[[@CR64]\]. While the results were mixed, with paracetamol allowing for opioid sparing in some studies but not others, the authors acknowledged that the variability in effectiveness may have been due to inadequate paracetamol dosing and variable absorption seen with rectal paracetamol, and stressed the importance of appropriate paracetamol dosing and route of administration \[[@CR64]\].

Clinical Trial Data {#Sec12}
-------------------

Clinical data for paracetamol 15 mg/kg in children with pain are summarized in Table [2](#Tab2){ref-type="table"}. Paracetamol has been compared with ibuprofen \[[@CR39], [@CR65]--[@CR68]\], ketoprofen \[[@CR69]\], naproxen \[[@CR70]\], and codeine \[[@CR66]\] in this setting. Studies of the use of paracetamol in pain show that paracetamol is generally as effective as ibuprofen, naproxen, and ketoprofen in reducing pain \[[@CR39], [@CR65], [@CR69], [@CR70]\]. In two studies, there was a significant difference between paracetamol and ibuprofen, with one study favoring ibuprofen \[[@CR66]\], and one favoring paracetamol \[[@CR68]\] (Table [2](#Tab2){ref-type="table"}). Also, when used a single agents, paracetamol was as effective as codeine at reducing pain caused by musculoskeletal injury \[[@CR66]\]. Generally, paracetamol was more effective than placebo at reducing pain \[[@CR39], [@CR68], [@CR69]\]. In the treatment of migraine, both paracetamol and ibuprofen were more effective than placebo at reducing headache pain \[[@CR67]\]. As for the clinical trials in fever, the tolerability of paracetamol was similar to that of ibuprofen, naproxen, ketoprofen, used for short-term treatment, and placebo (Table [2](#Tab2){ref-type="table"}).Table 2Summary of clinical trials of paracetamol for treatment of pain in childrenStudy (design; setting)Patients (*N*; age range)Treatments (*n*)RegimenEfficacy endpointEfficacy results (PARA vs. comparator)Adverse events (PARA vs. comparator)For pain Clark et al. \[[@CR66]\]. (R, PG; ED)MSK trauma (336; 6--17 years)PARA 15 mg/kg (112)\
IBU 10 mg/kg (112)\
COD 1 mg/kg (112)Single doseChange in pain VAS at 60 minChange in pain VAS at 60 min:\
--12 vs. --24 vs. --11 (both *P* ≤ 0.001 vs. IBU)Any AE:\
7.7% vs. 10.9% vs. 16.2% Cukiernik et al. \[[@CR70]\]. (R, DB, PG; OP)Soft tissue injuries to the ankle (77; 8--14 years)PARA 15 mg/kg (36)\
NAP 5 mg/kg (41)5 daysChange in disability and pain VAS at day 7Change in disability VAS at day 7:\
From 7.4 to 1.0 vs. from 7.2 to 1.4 (*P* = 0.21)\
Change in pain VAS at day 7:\
From 6.4 to 0.5 vs. from 6.8 to 0.7 (*P* = 0.21)Any AE:\
16.7% vs. 9.8% Mahgoobifard et al. \[[@CR68]\]. (R, DB, PG, PC; post-op)Tonsillectomy (60; 4--12 years)PARA 15 mg/kg (18)\
IBU 10 mg/kg (21)\
PL (21)Single dosePost-op pain (CHEOPS)Post-op CHEOPS score:\
7.05 vs. 8.14 vs. 8.36 (both p = 0.001)NR Ruperto et al. \[[@CR69]\]. (R, DB/OL, PC; OP)Pharyngotonsillitis (97; 6--12 years)PARA 12 mg/kg^a^ (34)\
KETO 40 mg^b^ (33)\
PL (32)Single doseChild-reported SPIDDifference in child-reported SPID:\
PARA vs. PL (*P* \< 0.05)\
PARA vs. KETO (NS)No serious AEs reported Salmassian et al. \[[@CR39]\]. (R, OL, PG; dental surgery)Orthodontic tooth movement (60; 12--18 years)PARA 600 mg (21)\
IBU 400 mg (19)\
PL (20)Multiple dosesPain VAS at peak pain after placement (19 h)Mean VAS at 19 h:\
3.75 vs. 4.79 vs. 5.23NR Shepherd et al. \[[@CR65]\]. (R, PG; ED)Acute limb fractures (72; 5--14 years)PARA 15 mg/kg^c^ (43)\
IBU 10 mg/kg^d^ (29)48 hChild-reported pain scores using 'Faces' pain scaleMean pain score:\
2.8 vs. 2.7 (*P* = 0.73)No AEs with PARA\
IBU reported vomiting (2), tiredness (1) and dizziness (1)For migraine Hamalainen et al. \[[@CR67]\]. (R, DB, CO, PC; OP)Migraine (88; 4--15.8 years)PARA 15 mg/kg\
IBU 10 mg/kg\
PLSingle doseReduction in severe or moderate headacheReduction in severe or moderate headache:\
54% vs. 68% vs. 37%Any AE:\
4.8% vs. 9.9% vs. 11.1%*CHEOPS* Children's Hospital of Eastern Ontario Pain Scale, *CO* crossover, *COD* codeine, *DB* double blind, *ED* emergency department; *IBU* ibuprofen, *MSK* musculoskeletal, *NAP* naproxen, *NR* not reported, *ND* not significant, *OL* open label, *OP* outpatient, *PARA* paracetamol, *PC* placebo-controlled, *PG* parallel group, *PL* placebo, *post*-*op* post-operative, *R* randomized, *SPID* sum of pain intensity differences of the CSTP intensity scale by the child, *VAS* visual analog scale^a^Syrup^b^Lysine salt sachet^c^Every 4 h^d^Every 8 h

A systematic review of 17 clinical trials showed that single-dose paracetamol 7--15 mg/kg had similar analgesic effect to ibuprofen 4--10 mg/kg in moderate to severe pain \[[@CR71]\]. Similarly, a systematic review of 10 clinical trials in the use of paracetamol 15 mg/kg to treat migraine showed that paracetamol is as effective as ibuprofen and nimesulide at reducing migraine symptoms, and more effective than placebo with a similar tolerability profile \[[@CR72]\].

Tolerability and Safety {#Sec13}
=======================

The WHO has highlighted the need for long-term safety data for paracetamol and ibuprofen \[[@CR18]\]. The adverse event profile of paracetamol vs. active comparators and placebo in the treatment of fever and pain and migraine is outlined in detail in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Generally, the adverse events associated with paracetamol were of similar or lesser frequency than active comparators; in some cases, paracetamol recipients had similar levels of AEs to NSAIDs \[[@CR34], [@CR70]\] but in most cases the incidence of general AEs was lower \[[@CR40], [@CR65], [@CR66]\]. NSAIDs typically had a higher incidence of gastrointestinal AEs than paracetamol, and the same also occurs even when they are used for short term \[[@CR34], [@CR40], [@CR59], [@CR65]\].

Generally, paracetamol is a very safe drug that is used extensively for the treatment of fever and pain worldwide. Government body guidelines state that paracetamol is safe for use throughout pregnancy; indeed, Italian authorities have designated it as the drug of choice for pain relief when administered at therapeutic doses (\<3 g/day) to pregnant women. Data suggests that paracetamol use during pregnancy does not result in congenital anomalies, and it is not contraindicated during breastfeeding. Furthermore, paracetamol can be effective in the management of ductus arteriosus in neonates, achieving high rates of ductal closure in the absence of adverse events \[[@CR73]\]. While there may be an increased risk of asthma and behavioral issues such as attention-deficit disorder with paracetamol use in pregnancy, these results have yet to be confirmed and are likely subject to confounding factors \[[@CR74]\]. The association may be a consequence of reverse causality bias \[[@CR75]\] or the influence of respiratory tract infections during pregnancy \[[@CR76], [@CR77]\].

Paracetamol toxicity can result in cases of overdose or where there are underlying conditions present \[[@CR78]\]. As with any drug, care must be used when administering paracetamol to children who may be suffering from dehydration \[[@CR79]\], malnutrition, or receiving concomitant medications \[[@CR18]\]. Chronic overdosing of paracetamol is linked to hepatic injury prompted by the paracetamol metabolite *N*-acetyl benzoquinone (NAPQI) and necessitates prompt *N*-acetylcysteine treatment \[[@CR9]\], however, severe liver injury with short courses of supratherapeutic doses is rare \[[@CR80]\]. Toxicity in children tends to occur after administration of single doses ranging from 120 to 150 mg/kg (Fig. [3](#Fig3){ref-type="fig"}), which is 10--15 times the recommended dosage \[[@CR78]\], even though idiosyncratic reactions associated to increased activity of the hepatic cytochrome P450 detoxifying system have been reported \[[@CR85]\]. Sustained dosing (\>1 day) with \>90 mg/kg/day (whereas the recommended dosing 60 mg/kg/day) puts children aged \<2 years at high risk for hepatotoxicity \[[@CR81]\]. Case reports describe children presenting with paracetamol toxicity after sustained dosing of 100--367 mg/kg/day \[[@CR81]\]. A recent study conducted in Australia and New Zealand revealed that hepatic failure due to paracetamol ingestion occurred in children mostly as a result of medication errors such as doses in excess of 120 mg/kg/day, double dose, too frequent administration, coadministration of other medicines containing paracetamol or regular paracetamol for up to 24 days \[[@CR82]\]. Also, as far as the potential risk of asthma and allergy in children treated with paracetamol is concerned, a clear causative role still needs to be unequivocally demonstrated because the initial paracetamol use--asthma incidence association \[[@CR86]\] has been recently diminished by considering respiratory tract infection as a confounding factor \[[@CR87]\]. Finally, results from recent clinical trials indicate that prophylactic use of paracetamol to prevent febrile reactions after immunization is not indicated because of the risk of reduced immunoglobulin production \[[@CR88]\].Fig. 3Time--concentration relationship after multiple paracetamol 15 mg/kg oral doses. Oral paracetamol 15 mg/kg every 6 h allows achievement of analgesic plasma concentrations well beneath (about tenfold) those inducing toxicity

Conclusions {#Sec14}
===========

Due to the pharmacology of paracetamol, it is important to choose an appropriate dose to get maximum efficacy while minimizing adverse effects. In children, paracetamol 15 mg/kg is the appropriate dose to use for treatment of fever. In the treatment of pain in children, the minimum dose of paracetamol that should be used is 15 mg/kg. According to WHO guidelines, the only available option for pain management in children below 3 months of age is paracetamol; the 10 mg/kg dose every 4--6 h should be recommended in this case \[[@CR18]\]. For the effective control of pain, paracetamol should be given as a scheduled dose over time, and not administered at need. The correct dose of paracetamol provides effective treatment of pain and fever that is equivalent to that seen with NSAIDs, making it an effective and safer treatment option in this setting.

Only paracetamol and ibuprofen appear recommended for reduction of fever in children \[[@CR15]\]. It is not recommended to use them in combination or alternating paracetamol and ibuprofen. Also, whereas ibuprofen is not approved for use in children under three months of age and is contraindicated in patients with chickenpox and in those with dehydration and pneumonia, paracetamol can be used from birth and in patients with dehydration \[[@CR13], [@CR14]\]. As for analgesia in children suffering from mild-to-moderate pain, paracetamol appears the drug of choice with an optimal dosage of 15 mg/kg every 4--6 h (no more than 4 times per day) \[[@CR83]\]. Of note, paracetamol is also the drug of choice for the treatment of mild-to-moderate pain in neonates \[[@CR83]\]. Finally, to avoid toxicity only standard doses should be used, with doses calculated according to weight and age; attention must also be paid to any clinical factors or concomitant medications that may increase the risk of toxicity.
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